Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE, Mosquera JM. Fontugne J, et al. Among authors: macdonald ty. JCI Insight. 2022 Feb 22;7(4):e155309. doi: 10.1172/jci.insight.155309. JCI Insight. 2022. PMID: 35050902 Free PMC article.
Molecular alterations in prostate cancer and association with MRI features.
Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE. Lee D, et al. Among authors: macdonald ty. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):430-435. doi: 10.1038/pcan.2017.33. Epub 2017 Aug 1. Prostate Cancer Prostatic Dis. 2017. PMID: 28762374
SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. Blattner M, et al. Among authors: macdonald ty. Neoplasia. 2014 Jan;16(1):14-20. doi: 10.1593/neo.131704. Neoplasia. 2014. PMID: 24563616 Free PMC article.
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM. Park K, et al. Among authors: macdonald ty. Hum Pathol. 2014 Oct;45(10):2136-43. doi: 10.1016/j.humpath.2014.06.008. Epub 2014 Jun 26. Hum Pathol. 2014. PMID: 25128228 Free PMC article.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Beltran H, et al. Among authors: macdonald ty. Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130. Cancer Discov. 2011. PMID: 22389870 Free PMC article.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Barbieri CE, et al. Among authors: macdonald ty. Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279. Nat Genet. 2012. PMID: 22610119 Free PMC article.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA. Beltran H, et al. Among authors: macdonald ty. Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5. Eur Urol. 2013. PMID: 22981675 Free PMC article.
Punctuated evolution of prostate cancer genomes.
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. Baca SC, et al. Among authors: macdonald ty. Cell. 2013 Apr 25;153(3):666-77. doi: 10.1016/j.cell.2013.03.021. Cell. 2013. PMID: 23622249 Free PMC article.
30 results